Study #2021-0253
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
MD Anderson Study Status
Enrolling
Treatment Agent
DCC-3116, Trametinib, Binimetinib, Sotorasib
Description
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.